CTIS.eu › Cities › France › Paris
Paris
France
2,286 total trials
1,022 recruiting
Filter these 2,286 trials by phase, condition, sponsor and more.
Open in Search →
2024-511202-23-00
4
2024-10-31
Epithelial ovarian cancer that progressed on prior PARP inhibitor ther
2023-508096-36-00
5
2024-10-30
atopic dermatitis
2024-516965-35-00
5
2024-10-28
Immune system disorders
2023-508895-13-00
4
2024-10-25
Amyotrophic Lateral Sclerosis (ALS)
2023-508636-61-00
5
2024-10-24
Crohn’s Disease
2024-515870-28-00
5
2024-10-22
Moderate to severe systemic lupus erythematosus
2024-515299-11-00
5
2024-10-18
SMALL BOWEL ADENOCARCINOMA
2024-511796-15-00
5
2024-10-16
Acetylcholine Receptor Binding Antibody Seronegative Generalized Myast
2024-511213-38-00
4
2024-10-15
Coeliac disease
2023-507891-31-00
10
2024-10-11
Human Immunodeficiency Virus (HIV-1) infection
2024-511304-16-00
4
2024-10-10
Newly Diagnosed Advanced Stage Follicular Lymphoma
2023-505278-13-00
4
2024-10-01
-women with an inflammatory HCA proven at histology and with at least
2023-507655-30-00
5
2024-09-27
Obesity
2023-503692-24-00
5
2024-09-25
Cutaneous Lupus Erythematosus
2022-502269-13-00
4
2024-09-24
Glioma
2023-507851-31-00
5
2024-09-23
Immunoglobulin A Nephropathy (IgAN)
2023-505507-22-00
10
2024-09-12
Primary aldosteronism
2024-513645-37-00
5
2024-09-05
Adult patients with indication for conventional cardiac surgery (CABG,
2023-509190-23-00
5
2024-09-03
Atherosclerotic Cardiovascular Disease
Elevated lp(a)
2024-510908-37-00
5
2024-08-28
KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (
2023-505650-17-00
5
2024-08-27
Symptomatic Obstructive Hypertrophic Cardiomyopathy
2023-504176-25-00
9
2024-08-08
Acute Myeloid Leukemia
2023-505423-31-00
5
2024-08-08
advanced or metastatic gastric adenocarcinoma, gastroesophageal juncti
2023-505673-32-00
5
2024-08-05
Hypophosphatasia
Showing 1,345–1,368 of 2,286 trials